Effect of troglitazone on endothelial function in type 2 diabetic patients

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 1, 2002, Pages 34-38

  Takase, Hiroyuki ^a   Hakamata, Mutsumi ^a   Toriyama, Takayuki ^a   Hayashi, Kunihiko ^a   Gotoa, Takatoshi ^a   Sato, Koichi ^a   Ueda, Ryuzo ^a   Dohi, Yasuaki ^a  

^a Enshu General Hospital   (Japan)

Author keywords

CAS 97322 87 7; Diabetes mellitus, endothelial function; Lysophosphatidylcholine; Nitric oxide; Noscal ; Troglitazone, effect on endothelial function, humans

Indexed keywords

ANTIOXIDANT; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; NITRATE; NITRIC OXIDE; NITRITE; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; VASODILATATION;

EID: 0036148083     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299853     Document Type: Article

References (21)

1. Diabetes mellitus and coronary heart disease in the elderly
2. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity
3. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: Relationship to endothelium dependent relaxation
4. Lysophosphatidylcholine: A chemotactic factor for human monocytes and its potential role in atherogenesis
5. Minimally modified iow density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells
6. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells
7. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: Effect of lysophosphatidylcholine composition on vascular relaxation
8. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
9. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats
10. Inhibition of oxidation of low density lipoprotein by troglitazone
11. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
12. 15N]nitrate in biological fluids
13. Some statistical methods useful in circulation research
14. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans
15. The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro
16. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
17. Nitric oxide release accounts for insulin's vascular effects in humans
18. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone
19. 2+ currents and not endothelial nitric oxide production
20. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells